Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Co-treatment With Aromatase Inhibitor or Progestin in Recurrent Implantation Failure
NCT05437471Completed
- Sponsor
- Hospital Canselor Tuanku Muhriz
- Start
- Jan 2020
- Primary completion
- Dec 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of letrozole and dydrogesterone in Recurrent Implantation Failure (RIF) (3 arms), sponsored by Hospital Canselor Tuanku Muhriz. Primary endpoint: Endometrial abv3-integrin expression expressions at 12 months. Started Jan 2020; status: completed.
02
Drugs
letrozoledydrogesterone
03
Conditions
Recurrent Implantation Failure (RIF)
Beyond the preview
Go deeper on NCT05437471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05437471.